The precedent is that it's a requirement before progressing to the P3 trial.
As per the AGM meeting presentation (and roadshow presos) the meeting is a FDA Type B meeting for the end of Phase 2 for Phelan McDermid syndrome, to review and agree the next steps and requirements for Phase 3 trials.
Type B detail here: https://www.fda.gov/media/72253/download
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
Neuren Media and Analyst Coverage, page-1352
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.69 |
Change
0.035(0.26%) |
Mkt cap ! $1.746B |
Open | High | Low | Value | Volume |
$13.70 | $13.76 | $13.63 | $236.6K | 17.30K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 270 | $13.68 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.69 | 199 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 203 | 13.650 |
5 | 288 | 13.640 |
4 | 343 | 13.630 |
4 | 566 | 13.620 |
4 | 819 | 13.610 |
Price($) | Vol. | No. |
---|---|---|
13.670 | 86 | 5 |
13.680 | 329 | 4 |
13.690 | 464 | 8 |
13.700 | 431 | 4 |
13.710 | 256 | 2 |
Last trade - 10.57am 17/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |